Picture


Bruce Brook of CSL in second quartile of Large MCap Director Scorecard for past year


Bruce Brook's performance as Director of CSL is ranked in the second quartile of BuySellSignals News Bites' Large MCap performers for the past year; a percentile ranking of 51.9. The shares were up 8.7% in AUD terms for the year ended August 21, 2019. In USD terms the price rise was 0.9%.

SECTION 1 BIOGRAPHY BRUCE BROOK, INDEPENDENT NON-EXECUTIVE DIRECTOR

Mr Bruce Brook was appointed to the CSL Board in August 2011. He is currently Chairman of Programmed Maintenance Services Limited and a Director of Newmont Mining Corporation. Mr Brook has previously been Chairman of Energy Developments Limited and a Director of Boart Longyear Limited, Lihir Gold Limited and Consolidated Minerals Limited. During his executive career, he was Chief Financial Officer of WMC Resources Limited and prior to that the Deputy Chief Financial Officer of the ANZ Banking Group.

Mr Brook is Chairman of the Audit and Risk Management Committee and a member of the Nomination Committee.

Remuneration
Cash salary and fees Total 2013: $ 213,582

SECTION 2 CSL LIMITED ACTIVITIES

CSL Limited (CSL) is a global biotechnology company that develops and delivers innovative medicines that save lives, protectpublic health and help people with life-threatening medical conditions live full lives. The operational businesses include CSL Behring and Seqirus provides life saving products to more than 60 countries and employs 22,000 people. The Group operates predominantly in Australia, the USA, Germany, the United Kingdom and Switzerland.

SECTION 3 OTHER DIRECTORS OF CSL LIMITED

Paul Perreault, Chief Executive Officer & Managing Director
David Lamont, Chief Financial Officer
Megan Clark, Director
David Anstice, Director
Tadataka Yamada, Director
Christine OReilly, Independent Director
Marie McDonald, Independent Director
Bruce Brook, Independent Non-Executive Director
Brian McNamee, Independent Non-Executive Director
Abbas Hussain, Independent Non-Executive Director
Paul McKenzie, Chief Operating Officer
Ed Bailey, Company Secretary
Fiona Mead, Company Secretary

SECTION 4 RECENT NEWS ON DIRECTORS

4.1 SHAREHOLDER VALUE ADDED BY DIRECTORS

01 July 2019
Paul Perreault brings four-bagger value to CSL

Paul Perreault was appointed CEO of CSL (ASX:CSL) six years ago on July 01, 2013. The present value of AUD1,000 (PV1000) invested on the appointment date is $A4,308, for a capital gain of $A2,912 and dividend reinvested of $A395. In the same period the shares were up 291.2% from $A55.4 to $A216.6.

SECTION 5 CSL LIMITED PRICE PERFORMANCE SCORECARD (Australian:CSL):

5.1 The Past Four Years
CSL rises for a fourth consecutive year, a four-year rise of 177%
CSL Limited (ASX:CSL), extended its rise from 19.3% three years ago to 75.2% two years ago to 8.7% a year ago. In the past four years it has risen $A150.30 (176.8%), compared with the All Ordinaries Index which rose 1,347.8 points (25.8%) in the four years for a relative price increase of 151.0%.

5.2 Moving Annual Return (Past 5 years)
Based on a dynamic start date of 5 years ago, the real rate of return has averaged 31.7%. The Moving Annual Return has consistently exceeded 9%.
CSLClose (AUD)Dividends (AUD)Capital Gain %% YieldAnnual Return %
Aug 21235.32.488.71.19.9
1 Yr ago216.381.9272.51.574.1
2 Yrs ago125.421.7221.11.722.7
3 Yrs ago103.581.7119.4221.4
4 Yrs ago86.741.3928.52.130.6


Close 5 years ago $A67.49

5.3 Present Value of $A1000 invested in the past
The present value of $A1000 invested a year ago is $A1,101
PV$10001-week1-month1-year
CSL.ASX1,0061,0611,101
All Ordinaries Index9879491,030


5.4 Trailing Price Change %
1-Year price change of 8.7% for CSL outperformed the change of 2.1% in the All Ordinaries Index for a relative price change of 6.6%.
Price Change %1-Month3-Month1-Year
CSL6.114.18.7
Pharmaceuticals & biotechnology sector4.013.59.4
All Ordinaries Index-3.1-0.22.1

SECTION 6 CSL LIMITED FINANCIALS AND GROWTH PERFORMANCE SCORECARD (Australian:CSL):

6.1 Key Financials (All figures percent)
EPS Growth has improved from -7.7% in 2016 to 11.0% in 2019 and Operating Margin has improved from 26.6% in 2016 to 28.5% in 2019.
CSLRevenue GrowthEPS GrowthOperating MarginROE
20197.91128.536.5
201813.929.930.142.4
201710.29.324.342.3
201612-7.726.648.4


6.2 Revenue and Net Profit
In the last 3 years Compound Annual Growth Rate (CAGR) averaged 10.3% for Total Revenue and 13.5% for Net Profit.
DescriptionAnnual ($US B)3-year Avg ($US B)3-year CAGR %
Total Revenue8.57.810.3
EBITDA2.32.112.9
Operating Profit2.32.112.9
Net Profit1.81.713.5

CAGR = Compound Annual Growth Rate

6.3 Performance (All figures in %)
Net Profit Margin 3-year average is 21.8% and Return on Assets 3-year average is 15.4%.
DescriptionAnnual3-year Avg
EBITDA Margin28.527.6
Operating Profit Margin28.527.6
Net Profit Margin23.421.8
Return on Equity36.540.4
Return on Assets15.615.4
Return on Capital Employed23.123.8


6.4 High Performance Indicators and rank of CSL in the Australian market:
DescriptionCSL ValueRank In Australian Market
Turnover in Quarter$A10.2 billionIn Top 1%
Return on Assets [ROA] %15.6In Top Quartile
Price/MAP2001.18In Top Quartile
Return on Capital Employed [ROCE] %23.1In Top Quartile
Volatility %1.4In Top Quartile
Price/MAP501.06In Top Quartile

SECTION 7 CSL LIMITED GLOBAL RANK (Australian:CSL):

7.1 Global Rank
Rank in the All Ordinaries Index [out of 493 stocks]
DescriptionValueRank
MCap (US$)72.3B3
Total Assets (US$)12.3B29
Revenue (US$)8.5B19
Net Profit (US$)1.8B8
Return on Equity %36.520
Net Profit Margin %23.495
Price to Book21.4376
Price Earnings37.6290
Yield %1.1334
PV$1000 (1Year) US$*1,021213
% Change YTD27.9143

Aug 21, 2019: AUD 1 equals USD 0.6782

ISIN: AU000000CSL8

CSL Limited
PermID: 4295856855

Source: www.BuySellSignals.com